Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone for Etomidate-Induced Adrenal Insufficiency in ICU
NCT00862381Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Oct 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydrocortisone in Acute adrenal insufficiency (AAI), sponsored by CHU Grenoble Alpes. Primary endpoint: Reduction of 50% of the proportion of patients with a SOFA of 3 or 4 at 48 hours. Started Oct 2008; status: completed.
02
Drugs
hydrocortisone
03
Conditions
Acute adrenal insufficiency (AAI)
Beyond the preview
Go deeper on NCT00862381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862381.